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Abstract: Background: Neuropsychological screening becomes increasingly important for the evaluation
of subarachnoid hemorrhage (SAH) and stroke patients. It is often performed during the surveillance
period on the intensive (ICU), while it remains unknown, whether the distraction in this environment
influences the results. We aimed to study the reliability of the Montreal Cognitive Assessment (MoCA)
in the ICU environment. Methods: Consecutive stable patients with recent brain injury (tumor, trauma,
stroke, etc.) were evaluated twice within 36 h using official parallel versions of the MoCA (ΔMoCA). The
sequence of assessment was randomized into (a) busy ICU first or (b) quiet office first with subsequent
crossover. For repeated MoCA, we determined sequence, period, location effects, and the intraclass
correlation coefficient (ICC). Results: N = 50 patients were studied [n = 30 (60%) male], with a mean
age of 57 years. The assessment’s sequence [”ICU first” mean ΔMoCA -1.14 (SD 2.34) vs. ”Office
first” -0.73 (SD 1.52)] did not influence the MoCA (p = 0.47). On the 2nd period, participants scored
0.96 points worse (SD 2.01; p = 0.001), indicating no MoCA learning effect but a possible difference in
parallel versions. There was no location effect (p = 0.31) with ΔMoCA between locations (Office minus
ICU) of -0.32 (SD 2.21). The ICC for repeated MoCA was 0.87 (95% CI 0.79-0.92). Conclusions: The
reliability of the MoCA was excellent, independent from the testing environment being ICU or office.
This finding is helpful for patient care and studies investigating the effect of a therapeutic intervention
on the neuropsychological outcome after SAH, stroke or traumatic brain injury.
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Background: Neuropsychological screening becomes increasingly important for the
evaluation of subarachnoid hemorrhage (SAH) and stroke patients. It is often performed
during the surveillance period on the intensive (ICU), while it remains unknown, whether
the distraction in this environment influences the results. We aimed to study the reliability
of the Montreal Cognitive Assessment (MoCA) in the ICU environment.
Methods: Consecutive stable patients with recent brain injury (tumor, trauma, stroke,
etc.) were evaluated twice within 36 h using official parallel versions of the MoCA
(1MoCA). The sequence of assessment was randomized into (a) busy ICU first or (b) quiet
office first with subsequent crossover. For repeated MoCA, we determined sequence,
period, location effects, and the intraclass correlation coefficient (ICC).
Results: N= 50 patients were studied [n= 30 (60%) male], with a mean age of 57 years.
The assessment’s sequence [“ICU first” mean 1MoCA −1.14 (SD 2.34) vs. “Office first”
−0.73 (SD 1.52)] did not influence the MoCA (p = 0.47). On the 2nd period, participants
scored 0.96 points worse (SD 2.01; p = 0.001), indicating no MoCA learning effect but
a possible difference in parallel versions. There was no location effect (p = 0.31) with
1MoCA between locations (Office minus ICU) of −0.32 (SD 2.21). The ICC for repeated
MoCA was 0.87 (95% CI 0.79–0.92).
Conclusions: The reliability of the MoCA was excellent, independent from the testing
environment being ICU or office. This finding is helpful for patient care and studies
investigating the effect of a therapeutic intervention on the neuropsychological outcome
after SAH, stroke or traumatic brain injury.
Keywords: Montreal Cognitive Assessment, intensive care unit, reliability, neuropsychology, cognitive evaluation,
neuropsychological assessment, test quality, stroke
INTRODUCTION
Cognitive assessment is increasingly recommended in patients surviving aneurysmal subarachnoid
hemorrhage (aSAH) and is gradually becoming a part of routine clinical practice (1). The high
incidence of neuropsychological deficits after aSAH and their decisive impact on long-term
recovery are well-described in the literature (2).
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Screening of neuropsychological functions to estimate the
need for rehabilitation is often already performed during the
surveillance period on the intensive care unit (ICU). For this, the
Montreal Cognitive Assessment (MoCA) has been identified as
first choice among the short but comprehensive instruments (3,
4). It has found entry into national guidelines and the “Outcome
and Endpoints” recommendations by the National Institute of
Health (NIH)/National Institute of Neurological Disorders and
Stroke (NINDS) Common Data Elements (CDE) project (1, 5, 6).
Thus, the MoCA is likely to be increasingly applied in the future
but it remains unknown, whether the distraction in the ICU
environment might bias the results. Furthermore, information
on the MoCA test’s qualities derives from patients with mild
cognitive impairment or Parkinson’s disease (7, 8). Especially
the MoCA test-retest reliability has never been determined in
patients with acutely injured brains (9, 10).
This study set out to determine the test-retest reliability of
the MoCA in alert patients with recent brain injury. It also aims
to shed light on the question, whether the ICU environment
represents a significant bias to MoCA test results.
MATERIALS AND METHODS
We prospectively screened all patients suffering from acute
brain injury requiring in-hospital treatment at our department
between July 2017 and October 2017, e.g., for the (surgical)
treatment of intracranial tumors, hemorrhagic or ischemic
stroke, hydrocephalus or traumatic brain injury (TBI). The aim
was to study a cohort of non-SAH patients, which shares many
important characteristics of a typical SAH population, however.
Only alert adult patients (Glasgow Coma Scale ≥ 13)
with stable neurological as well as general health status, with
sufficient German language skills were enrolled from our regular
neurosurgery ward. Patients requiring intensive care were not
considered, as it would have been unsafe to test them in a
non-ICU environment. We also defined suspected fluctuation of
the neurological condition/vigilance, known psychiatric disease
with potential influence on the MoCA (e.g., dementia, bipolar
disorder), insufficient German language skills or need for sedative
medication interfering with the MoCA assessment as further
exclusion criteria.
Consenting patients were assessed twice within 36 h. The
sequence of assessment was determined by a computerized
automatic randomization process to distribute patients into (a)
busy ICU first or (b) quiet office first, with subsequent crossover
to the other location. Significant fluctuations in the neurological
or general health status between both neuropsychological
assessments were considered an exclusion criterion.
Abbreviations: aSAH, aneurysmal subarachnoid hemorrhage; CDE, Common
Data Elements; CI, confidence interval; CSF, cerebrospinal fluid; EQ-5D, EuroQol
5D (3L); ICC, intraclass correlation coefficient; ICU, intensive care unit;
MCID, minimum clinically important difference; MOCA, Montreal Cognitive
Assessment; mRS, modified Rankin Scale; NIH, National Institute of Health;
NIHSS, National Institute of Health Stroke Scale; NINDS, National Institute of
Neurological Disorders and Stroke; SD, standard deviation; TBI, traumatic brain
injury; VAS, visual analog scale.
Neuropsychological Examination
Full paper and pencil MoCA assessments were performed by
neuropsychologists, blinded for health-specific patient details.
In order to prevent from learning effects and to reduce false
reliability, we used the official GermanMoCA version for the first
assessment (ICU or office), and the additional version 2 for the
second assessment (ICU or office), as provided by http://www.
mocatest.org. MoCA administration and scoring were based on
a standard operating procedure. The same neuropsychologist
performed repeated assessments in a single patient to avoid inter-
rater reliability issues not attributable to the testing environment.
Testing Environments
Our Neurocritical Care Unit is a fully equipped 12-bed ICU
(room 1: eight beds with equipment for artificial ventilation;
room 2: four beds without equipment for artificial ventilation),
treating 1,200–1,400 critically ill patients with neurological
diseases annually and an occupancy rate of about 90%. In each
room, opaque but noise-permeable curtains separate patient
boxes to insure some privacy. As for normal clinical routine,
curtains were allowed closed during the “ICU assessment.”
The “Office assessment” took place in a quiet office on the
ward with closed door. Except for the neuropsychologist and
the patient, no additional person was allowed in the room
during assessment.
Statistical Considerations
The null hypothesis was that the MoCA results of the “ICU
assessment” do not differ from the MoCA results of the “Office
assessment.” The approach to the analysis was similar to that used
in the case-crossover design, where the location of assessment
(ICU vs. Office) is considered the independent variable. We
estimated three key effects: sequence, period (time point), and
location of testing. The statistical approaches were detailed
previously (10).
The clinical relevance of the difference in the MoCA
was appraised referring to the reported minimum clinically
important difference (MCID) of two points in both patients with
aSAH and Parkinson’s disease (8, 9).
The intraclass correlation coefficient (ICC) of repeated MoCA
was determined and interpreted according to Cichetti with ICC
< 0.40 (poor), 0.40–0.59 (fair), 0.60–0.74 (good), and 0.75–1.00
(excellent) (11).
Given the lack of previous data, no formal sample size
calculations were performed. We estimated that including 50
complete datasets would be sufficient (10).
Ethical Considerations
The Institutional Review Board “Kantonale Ethikkommission
Zürich” approved the study (BASEC 2017-00103). All patients
gave written informed consent. The study was conducted in
accordance with Good Clinical Practice (GCP) guidelines and the
1964 Helsinki declaration and its later amendments.
The study was registered under https://clinicaltrials.gov/
(Identifier NCT03032471) and themethodology with pre-defined
statistical plan was published (10).
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RESULTS
A total of n = 144 patients were screened, of which n = 77 were
not eligible and n= 10 refused participation.N = 57 patients gave
consent and were enrolled. N = 29 were randomized to the “ICU
first” and n = 28 to the “Office first” group. During the study,
seven patients had to be excluded (six were discharged before
the second assessment; one neurologically declined between both
assessments). Finally, complete data of n = 50 patients was
available for analysis (Figure 1).
Patient characteristics from both groups are summarized
in Supplementary Table 1. Randomization proved effective to
balance for all important baseline parameters, except for
patient sex and disease type. Mean MoCA was 24.8 (SD
4.1, range: 14–30; Supplementary Figure 1A) at first and
23.8 (SD 4.6, range 12–30; Supplementary Figure 1B) at
second assessment.
Effects of Sequence, Period, and Location
on MoCA Results
The mean difference in the MoCA for patients in the “ICU
first” group was −1.14 [standard deviation (SD) 2.34] and for
patients in the “Office first” group was −0.73 (SD 1.52; p =
0.47), indicating that sequence does not have an effect on the
MoCA score.
The mean difference between the MoCA scores at time point
1 and 2 was 0.96 (SD 2.01; p = 0.001), indicating that patients
scored about 1 point less during the second period.
Themean difference between theMoCA score at the office and
ICU was −0.32 (SD 2.21; p = 0.31), indicating that location has
no effect on the MoCA score (Table 1).
Intra-Class Correlation Coefficient
The individual ICC was 0.87 (95% CI 0.79–0.93), representing
an index for the reliability of different locations for each
individual. The average ICC was 0.93 (95% CI 0.88–0.96),
representing an index for the reliability of different locations on
average (Table 1).
MoCA Differences ≥2 Points (MCID)
There were 19 (38%) patients in whom the difference in MoCA
scores was ≥ 2. It should be noted that the standard deviation
of the differences was 2 (similar to the MCID) (9). Knowing
that the distribution of differences is normal, and 68% of values
of a normal distribution will lie within one standard deviation,
that means that ∼32% of differences in MoCA scores will be
considered to have surpassed the threshold to be considered a
clinically meaningful change (MCID).
TABLE 1 | Reliability measures of the MoCA, taking into account sequence, time
point, and location effects.
Sequence effect
ICU first: mean difference −1.14
(SD 2.34)




Mean difference (Time point 1 minus time point 2): 0.96 (SD 2.01) p = 0.001
Location effect
Mean difference (Office minus ICU): −0.32 (SD 2.21) p = 0.31
Intra-Class Correlation Coefficient (ICC)
Individual ICC: 0.87 95% CI: 0.79–0.93 p < 0.001
Average ICC: 0.93 95% CI: 0.88–0.96 p < 0.001
CI, confidence interval; ICU, intensive care unit; SD, standard deviation.
FIGURE 1 | Study profile. *Based on ascertainment log.
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DISCUSSION
This study set out to measure the agreement and reliability
of the MoCA test when applied to fifty consecutive patients
with acutely injured brains in the ICU vs. office environment.
Each patient was randomized to being tested in the office or
ICU first, served as his/her own control, and was analyzed
using crossover design methods. The study demonstrates that
there was no location effect on the MoCA results. In general,
the reliability of the MoCA was found to be excellent,
implying that the difference between the MoCA results of
both locations is very small (Table 1). Besides, the study finds
that there was no learning effect, but that there may be a
difference in the difficulty of the two official parallel versions of
the MoCA.
Importantly, the timing of the 1st or 2nd assessment
(morning vs. afternoon), the time lag between both
assessments, and the severity of headache at time
of the assessment was balanced between groups,
which is unlikely to have influenced the results
(Supplementary Table 1).
Patients with acute brain injury from various causes
were chosen as proxy for aSAH patients because of ethical
concerns (patient safety), not allowing for aSAH patients to
be randomly assigned to assessments on the ICU or in the
office. In aSAH patients, bed rest and careful control of
hemodynamics, oxygenation and temperature is recommended
during the acute phase to minimize the risks for delayed
cerebral ischemia. However, the heterogeneous group of
patients studied here, many of them having experienced stroke,
hydrocephalus and recent brain surgery, resemble well the
typical aSAH patient population. A cohort of stable and
alert patients with relatively low disease burden was studied
(Supplementary Table 1), as it was the aim of the work
to investigate the test-retest reliability and medical and/or
neurological deterioration between both evaluations would have
biased the results. Therefore, it is difficult to extrapolate the
findings on the complete population of ICU patients and
reliability of the MoCA in severely ill ICU patients might
be lower.
Early neuropsychological evaluation finds entry into the
management of a broad variety of acute central nervous system
disorders, and studying a heterogeneous patient sample allows
for generalizing the results to the wider neurosurgical population,
including patients suffering from other forms of stroke
or TBI.
CONCLUSIONS
In conclusion, the MoCA is a reliable tool when applied to alert
patients in an ICU environment. This is an important finding
for clinical patient care and studies investigating the effect of
a therapeutic intervention on the neuropsychological outcome
after aneurysmal subarachnoid hemorrhage, other types of stroke
or TBI.
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